High C-reactive protein/albumin ratio associated with reduced survival due to advanced stage of intrahepatic cholangiocarcinoma
-
- Kano Hisao
- Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan.
-
- Midorikawa Yutaka
- Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan.
-
- Song Peipei
- National Center for Global Health and Medicine, Tokyo, Japan.
-
- Nakayama Hisashi
- Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan.
-
- Moriguchi Masamichi
- Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan.
-
- Higaki Tokio
- Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan.
-
- Tsuji Shingo
- Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
-
- Takayama Tadatoshi
- Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan.
この論文をさがす
抄録
<p>C-reactive protein (CRP)- and albumin (Alb)-based scoring systems are available for predicting the prognosis of patients with diverse forms of gastrointestinal cancer, but their utility for patients with intrahepatic cholangiocarcinoma (ICC) is still unclear. This study aimed to elucidate whether a high CRP/Alb ratio is associated with the surgical outcome of ICC patients. Patients who underwent initial and curative resection for ICC were included in this study, and were divided into the High and Low CRP/Alb groups based on their preoperative CRP and Alb values. The surgical outcomes were compared between the two groups. The median CRP/Alb ratio amongst 88 patients was 0.033 (range, 0.019-3.636); 44 patients with CRP/Alb > 0.033 were allocated to the High CRP/Alb group and 44 patients were allocated to the Low CRP/Alb group. The operative data did not differ between the two groups, while the tumor status was more advanced in the High CRP/Alb group. The median overall survival was 2.4 years (95% CI, 1.4-3.3) and 8.9 years (3.8-NA) in the High and Low CRP/Alb groups, respectively (P < 0.001), and recurrence-free survival was 0.5 years (95% CI, 0.3-0.7) and 7.7 years (1.3-NA), respectively (P < 0.001). In a multivariate analysis, the independent factors for overall survival were High CRP/Alb (P = 0.017) and multiple nodules (P = 0.008). Taken together, the survival of ICC patients in the High CRP/Alb group was reduced compared to that of patients in the Low CRP/Alb group due to the advanced stage of the tumor as well as malnutrition.</p>
収録刊行物
-
- BioScience Trends
-
BioScience Trends 14 (4), 304-309, 2020-08-31
特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会